The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InThermo Fisher Scientific has announced a strategic collaboration with Singapore's Precision Health Research (PRECISE) to support the large-scale PRECISE-SG100K study. The partnership aims to advance population biobank research by providing cutting-edge proteomics technology and AI-driven analytics for early disease detection. The study will utilize the Olink PEA platforms and the Orbitrap Astral mass spectrometry system to ensure high-quality proteomic and clinical data. This initiative is designed to deepen the understanding of disease biology and improve precision medicine outcomes within the Singaporean population. The move solidifies Thermo Fisher's leadership in the high-growth biotechnology sector, potentially driving long-term revenue through specialized equipment and assay sales. Additionally, Seer Inc. will contribute to the project, providing integrated analytical solutions to meet the study's ambitious scientific goals.